Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Return on Capital Employed (2017 - 2025)

Historic Return on Capital Employed for Akebia Therapeutics (AKBA) over the last 9 years, with Q3 2025 value amounting to 0.08%.

  • Akebia Therapeutics' Return on Capital Employed rose 3200.0% to 0.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.08%, marking a year-over-year increase of 3200.0%. This contributed to the annual value of 0.34% for FY2024, which is 1000.0% down from last year.
  • Akebia Therapeutics' Return on Capital Employed amounted to 0.08% in Q3 2025, which was up 3200.0% from 0.0% recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Return on Capital Employed high stood at 0.08% for Q3 2025, and its period low was 0.94% during Q1 2022.
  • For the 5-year period, Akebia Therapeutics' Return on Capital Employed averaged around 0.41%, with its median value being 0.33% (2023).
  • As far as peak fluctuations go, Akebia Therapeutics' Return on Capital Employed tumbled by -3500bps in 2021, and later skyrocketed by 7300bps in 2023.
  • Akebia Therapeutics' Return on Capital Employed (Quarter) stood at 0.87% in 2021, then soared by 66bps to 0.3% in 2022, then fell by -12bps to 0.33% in 2023, then fell by -14bps to 0.38% in 2024, then soared by 121bps to 0.08% in 2025.
  • Its last three reported values are 0.08% in Q3 2025, 0.0% for Q2 2025, and 0.13% during Q1 2025.